First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $4.86M, compared with $0 a year earlier.
Context
- Other current liabilities amounted to 1.7% of total assets at the end of Q1 FY2026.
- Other current liabilities increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 7.42M | +61.5% |
| FY2023 | 2023-12-31 | 4.59M | — |
Other Current Liabilities vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 other current liabilities of $4.86M is the 6th highest of the 10 companies compared; the peer median is $4.86M.
- Other current liabilities amounts to 1.7% of total assets for TRAX, versus a peer median of 2.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $104.02M | +892.5% | +263.2% | 13.7% | |
| Mar 2026 | $26.53M | +408.5% | +27.3% | 8.0% | |
| Mar 2026 | $6.06M | -39.9% | -8.8% | 3.0% | |
| Mar 2026 | $5.53M | +323.0% | +39.7% | 2.9% | |
| Mar 2026 | $4.86M | +268.5% | +29.8% | 3.3% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $4.86M | — | — | 1.7% |
| Jun 2026 | $2.67M | — | — | 2.1% | |
| Mar 2026 | $2.2M | -13.5% | +619.0% | 0.5% | |
CLYMClimb Bio, Inc. | Mar 2026 | $1.96M | — | — | 1.3% |
| Jun 2026 | $0 | — | -42.4% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $4.86M | +295.8% | +29.8% | 2.9% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.